Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Spartanburg Regional Medical Center
Forest City, North Carolina, United States
- M D Anderson Cancer Center
Houston, Texas, United States
- Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jan 2021
- Primary completion
- 1 Dec 2023
- Completion
- 1 Dec 2023
- Last update posted
- 6 May 2024
- Registered enrollment
- 8
- Registry id
- NCT04088188
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.